易聯眾(300096.SZ)孫公司擬與山東微醫簽訂550萬元技術開發(委託)合同
格隆匯12月11日丨易聯眾(300096.SZ)公佈,公司控股孫公司福建易聯眾保睿通信息科技有限公司(“保睿通”)擬與山東微醫泰山慢病互聯網醫院有限公司(“山東微醫”)簽訂《技術開發(委託)合同》,由山東微醫委託保睿通研究開發泰安市醫保智能控費系統建設項目,合同總金額為人民幣550萬元。
此次公司與山東微醫簽訂的《技術開發(委託)合同》主要內容如下:
甲方:山東微醫泰山慢病互聯網醫院有限公司;乙方:福建易聯眾保睿通信息科技有限公司
合作內容:由甲方委託乙方研究開發泰安市醫保智能控費系統建設項目,實現該系統在泰安市共38家二級以上醫院及醫保中心端的部署上線工作。合作方式:乙方應在合同生效後十五日內向甲方提交研究開發計劃,並按合同約定的進度完成項目建設工作。甲方應向乙方提供相關技術資料並提供相應協助。此次合作價格總額為人民幣550萬元。
上述關聯交易屬於正常的、必要的商業交易行為,對公司的獨立性不會產生影響。交易價格參照市場價格,經雙方協商確定,實行市場定價,價格公允,不存在利用關聯方關係損害上市公司利益的行為,也不存在損害公司合法利益及向關聯方輸送利益的情形。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.